Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants

Trends in Pharmacological Sciences

Volumn 30, Issue 6, 2009, Pages 287-295

  Aimanianda, Vishukumar ^a   Haensler, Jean ^b   Lacroix Desmazes, Sébastien ^c,d,e   Kaveri, Srini V ^c,d,e   Bayry, Jagadeesh ^c,d,e  

^a INSTITUT PASTEUR   (France)

^b SANOFI PASTEUR   (France)

^c INSERM   (France)

^d CENTRE DE RECHERCHE DES CORDELIERS   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALUMINUM; ALUMINUM SALT; CD40 ANTIGEN; CD86 ANTIGEN; CHEMOKINE; CPG OLIGODEOXYNUCLEOTIDE; CRYOPYRIN; CYTOKINE; DNA VACCINE; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE DERIVATIVE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MEMBRANE COFACTOR PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHORYL LIPID A; POTASSIUM ION; REACTIVE OXYGEN METABOLITE; TETANUS TOXOID; UNCLASSIFIED DRUG; UNINDEXED DRUG; URIC ACID; WART VIRUS VACCINE;

CELL ACTIVATION; DENDRITIC CELL; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DESIGN; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; INFLAMMATORY CELL; INNATE IMMUNITY; MACROPHAGE ACTIVATION; MONOCYTE; NONHUMAN; PHAGOLYSOSOME; POTASSIUM TRANSPORT; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE ACTIVATION; TISSUE INJURY; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, INNATE;

EID: 68949086546     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2009.03.005     Document Type: Review

References (59)

1. Guy B. The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol. 5 (2007) 505-517
2. Trombetta E.S., and Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu. Rev. Immunol. 23 (2005) 975-1028
3. Zhu J., and Paul W.E. CD4 T cells: fates, functions, and faults. Blood 112 (2008) 1557-1569
4. Lindblad E.B. Aluminium compounds for use in vaccines. Immunol. Cell Biol. 82 (2004) 497-505
5. Brewer J.M., et al. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J. Immunol. 163 (1999) 6448-6454
6. Pollock K.G., et al. Interleukin-18 plays a role in both the alum-induced T helper 2 response and the T helper 1 response induced by alum-adsorbed interleukin-12. Immunology 108 (2003) 137-143
7. Jordan M.B., et al. Promotion of B cell immune responses via an alum-induced myeloid cell population. Science 304 (2004) 1808-1810
8. Wang H.B., and Weller P.F. Pivotal advance: eosinophils mediate early alum adjuvant-elicited B cell priming and IgM production. J. Leukoc. Biol. 83 (2008) 817-821
9. -/- mice: enhanced affinity maturation but impaired antibody persistence. J. Immunol. 164 (2000) 4522-4532
10. -/- mice is rescued by adjuvants without improvement in germinal center development. J. Immunol. 165 (2000) 3119-3127
11. Francis J.N., and Durham S.R. Adjuvants for allergen immunotherapy: experimental results and clinical perspectives. Curr. Opin. Allergy Clin. Immunol. 4 (2004) 543-548
12. Eisenbarth S.C. Use and limitations of alum-based models of allergy. Clin. Exp. Allergy 38 (2008) 1572-1575
13. Morefield G.L., et al. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 23 (2005) 1588-1595
14. HogenEsch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 20 Suppl. 3 (2002) S34-S39
15. Gupta R.K., et al. In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid. Vaccine 14 (1996) 1412-1416
16. Weissburg R.P., et al. Characterization of the MN gp120 HIV-1 vaccine: antigen binding to alum. Pharm. Res. 12 (1995) 1439-1446
17. Rosado-Vallado M., et al. Aluminium phosphate potentiates the efficacy of DNA vaccines against Leishmania mexicana. Vaccine 23 (2005) 5372-5379
18. Regnstrom K., et al. Tetanus antigen modulates the gene expression profile of aluminum phosphate adjuvant in spleen lymphocytes in vivo. Pharmacogenomics J. 2 (2002) 57-64
19. Mosca F., et al. Molecular and cellular signatures of human vaccine adjuvants. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 10501-10506
20. Goto N., et al. Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties. Vaccine 15 (1997) 1364-1371
21. Ulanova M., et al. The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect. Immun. 69 (2001) 1151-1159
22. Seubert A., et al. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J. Immunol. 180 (2008) 5402-5412
23. Kool M., et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J. Exp. Med. 205 (2008) 869-882
24. Li H., et al. Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1β and IL-18 release. J. Immunol. 178 (2007) 5271-5276
25. + T cell differentiation by aluminum-containing adjuvants. Vaccine 25 (2007) 4575-4585
26. Pape K.A., et al. Inflammatory cytokines enhance the in vivo clonal expansion and differentiation of antigen-activated CD4+ T cells. J. Immunol. 159 (1997) 591-598
27. Yoshimoto T., et al. IL-18 induction of IgE: dependence on CD4+ T cells, IL-4 and STAT6. Nat. Immunol. 1 (2000) 132-137
28. Wild J.S., et al. IFN-γ-inducing factor (IL-18) increases allergic sensitization, serum IgE, Th2 cytokines, and airway eosinophilia in a mouse model of allergic asthma. J. Immunol. 164 (2000) 2701-2710
29. Rimaniol A.C., et al. Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type. Vaccine 22 (2004) 3127-3135
30. Franchi L., and Nunez G. The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1β secretion but dispensable for adjuvant activity. Eur. J. Immunol. 38 (2008) 2085-2089
31. Hamilton J.A., et al. Particulate adjuvants can induce macrophage survival, DNA synthesis, and a synergistic proliferative response to GM-CSF and CSF-1. J. Leukoc. Biol. 67 (2000) 226-232
32. Kool M., et al. Cutting Edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J. Immunol. 181 (2008) 3755-3759
33. Cunningham A.F., et al. Pinpointing IL-4-independent acquisition and IL-4-inffluenced maintenance of Th2 activity by CD4 T cells. Eur. J. Immunol. 34 (2004) 686-694
34. Gavin A.L., et al. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 314 (2006) 1936-1938
35. Shi Y., et al. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425 (2003) 516-521
36. Mariathasan S., et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440 (2006) 228-232
37. Ng G., et al. Receptor-independent, direct membrane binding leads to cell-surface lipid sorting and Syk kinase activation in dendritic cells. Immunity 29 (2008) 807-818
38. Hornung V., et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 9 (2008) 847-856
39. Martinon F., et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440 (2006) 237-241
40. 7 receptors. J. Biol. Chem. 276 (2001) 125-132
41. Eisenbarth S.C., et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453 (2008) 1122-1126
42. Li H., et al. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J. Immunol. 181 (2008) 17-21
43. Petrilli V., et al. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ. 14 (2007) 1583-1589
44. De Gregorio E., et al. Alum adjuvanticity: unraveling a century old mystery. Eur. J. Immunol. 38 (2008) 2068-2071
45. Seder R.A., and Hill A.V. Vaccines against intracellular infections requiring cellular immunity. Nature 406 (2000) 793-798
46. Ishii K.J., and Akira S. Toll or toll-free adjuvant path toward the optimal vaccine development. J. Clin. Immunol. 27 (2007) 363-371
47. Bayry J., et al. In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 10221-10226
48. Garcon N., et al. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines 6 (2007) 723-739
49. Cooper C.L., et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J. Clin. Immunol. 24 (2004) 693-701
50. Paavonen J., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 (2007) 2161-2170
51. Ting J.P., et al. The NLR gene family: a standard nomenclature. Immunity 28 (2008) 285-287
52. H17 cells. Nature 453 (2008) 1051-1057
53. LeBien T.W., and Tedder T.F. B lymphocytes: how they develop and function. Blood 112 (2008) 1570-1580
54. Mariathasan S., and Monack D.M. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat. Rev. Immunol. 7 (2007) 31-40
55. Yu H.B., and Finlay B.B. The caspase-1 inflammasome: a pilot of innate immune responses. Cell Host Microbe 4 (2008) 198-208
56. Martinon F., et al. Identification of bacterial muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome. Curr. Biol. 14 (2004) 1929-1934
57. Kanneganti T.D., et al. Pannexin-1-mediated recognition of bacterial molecules activates the cryopyrin inflammasome independent of Toll-like receptor signaling. Immunity 26 (2007) 433-443
58. Kanneganti T.D., et al. Critical role for Cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA. J. Biol. Chem. 281 (2006) 36560-36568
59. Kanneganti T.D., et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 440 (2006) 233-236